Molecular Imaging of Neuroendocrine Differentiation of Prostate Cancer: A Case Series
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Molecular Imaging of Neuroendocrine Differentiation of Prostate Cancer: A Case Series
Authors
Keywords
Fluorodeoxyglucose, Prostate-specific membrane antigen, Radionuclide therapy, Somatostatin receptor, Neuroedocrine differentiation of prostate cancer
Journal
Clinical Genitourinary Cancer
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-02-10
DOI
10.1016/j.clgc.2021.01.008
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
- (2020) Michael S Hofman et al. LANCET
- Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution
- (2019) Gonçalo Ferreira et al. CANCER IMAGING
- 177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient With Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation
- (2019) Majid Assadi et al. CLINICAL NUCLEAR MEDICINE
- The epigenetic and transcriptional landscape of neuroendocrine prostate cancer
- (2019) Alastair Davies et al. ENDOCRINE-RELATED CANCER
- Differential expression of glucose transporters and hexokinases in prostate cancer with a neuroendocrine gene signature: a mechanistic perspective for FDG imaging of PSMA-suppressed tumors
- (2019) Martin K. Bakht et al. JOURNAL OF NUCLEAR MEDICINE
- Molecular model for neuroendocrine prostate cancer progression
- (2018) Ruiqi Chen et al. BJU INTERNATIONAL
- [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
- (2018) Michael S Hofman et al. LANCET ONCOLOGY
- Cellular plasticity and the neuroendocrine phenotype in prostate cancer
- (2018) Alastair H. Davies et al. Nature Reviews Urology
- Neuroendocrine differentiation of prostate cancer leads to PSMA suppression
- (2018) Martin K Bakht et al. ENDOCRINE-RELATED CANCER
- The dark side of glucose transporters in prostate cancer: Are they a new feature to characterize carcinomas?
- (2017) Pedro Gonzalez-Menendez et al. INTERNATIONAL JOURNAL OF CANCER
- Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer
- (2017) Sergio Pedraza-Arévalo et al. PROSTATE
- Immunohistochemical Expression and Localization of Somatostatin Receptor Subtypes in Prostate Cancer with Neuroendocrine Differentiation
- (2017) D. Morichetti et al. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
- Neuroendocrine Prostate Cancer: Subtypes, Biology, and Clinical Outcomes
- (2017) Rahul Aggarwal et al. Journal of the National Comprehensive Cancer Network
- 68Ga-DOTATOC and 68Ga-PSMA PET/CT Unmasked a Case of Prostate Cancer With Neuroendocrine Differentiation
- (2016) Sirong Chen et al. CLINICAL NUCLEAR MEDICINE
- Metastatic Poorly Differentiated Prostatic Carcinoma With Neuroendocrine Differentiation
- (2015) Partha Sarathi Chakraborty et al. CLINICAL NUCLEAR MEDICINE
- Targeting Neuroendocrine Prostate Cancer: Molecular and Clinical Perspectives
- (2015) Panagiotis J. Vlachostergios et al. Frontiers in Oncology
- Utility of FDG-PET in clinical neuroendocrine prostate cancer
- (2014) Daniel E. Spratt et al. PROSTATE
- Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy
- (2011) R.J. Hicks CANCER IMAGING
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now